Backs FY24 revenue view up 1%-4%, consensus $4.22B. The company said, “The Company is updating its financial guidance for 2024, which was initially provided on February 14, 2024. Despite modest adjustments to the quarterly gating in 2024, the Company’s outlook for the year remains essentially unchanged and it is reaffirming revenue growth and non-GAAP earnings per share guidance, with the continued expectation that demand trends will improve modestly during the second half of the year. “
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- CRL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Charles River announces rare disease gene therapy collaboration with Axovia
- Charles River to perform plasmid production for Ship of Theseus
- Charles River extends gene therapy manufacturing alliance with NUS Medicine
- Charles River price target raised to $290 from $200 at Argus